Stocksigma LogoStocksigma Logo

Cohance Lifesciences Invests USD 10 Million in Subsidiary NJ Bio

Cohance Lifesciences has remitted USD 10 million via internal accruals to subscribe to 188,680 Compulsorily Convertible Preferred Stocks (CCPS) of its

Cohance Lifesciences Invests USD 10 Million in Subsidiary NJ Bio

Cohance Lifesciences Ltd 路 Others (Uncategorized) 路 19 Sept 2026, 12:04 am

Cohance Lifesciences Invests USD 10 Million in Subsidiary NJ Bio Cohance Lifesciences has remitted USD 10 million via internal accruals to subscribe to 188,680 Compulsorily Convertible Preferred Stocks (CCPS) of its US-based subsidiary, NJ Bio Inc., at USD 53.00 per share. The CCPS are convertible into equity after 3 years, with completion expected before the end of Sep'26. The capital infusion will fund growth initiatives and capex in NJ Bio's antibody-drug conjugate (ADC) CRDMO business. NJ Bio posted revenues of USD 20.6 million in CY23, USD 32.6 million in CY24, and USD 23.5 million in CY25.

Original exchange filing (PDF)

More announcements from Cohance Lifesciences Ltd

All Cohance Lifesciences Ltd announcements